ArticleOphthalmology science2026
Implementation of a Multidisciplinary Eye Clinic within a Cancer Center for Patients at Risk of Ocular Graft versus Host Disease.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Ocular graft-versus-host disease (oGVHD) affects approximately 50% of patients undergoing hematopoietic stem cell transplantation (HSCT). Guidelines for monitoring patients for oGVHD development are not clearly established. An oGVHD clinic at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC) was established to evaluate HSCT patients at risk of developing oGVHD. The objective of this study was to examine whether an integrated eye clinic corresponded with lower odds of developing oGVHD within 2 years post-HSCT. Design: A single-center retrospective longitudinal cohort study. Participants: One hundred eighty-three patients post-HSCT were included and compared patients treated before (n = 107) and after (n = 76) the UMGCCC Clinic opening in 2021. Methods: Ocular graft-versus-host disease odds within 2 years post-HSCT were compared between pre-UMGCCC and post-UMGCCC groups using multivariate logistic regression. A secondary analysis evaluated ophthalmic treatments initiated at the first post-transplant visit and their associations with oGVHD incidence. Bayesian logistic regression estimated posterior probability. Main Outcome Measures: We assessed the odds of oGVHD 2 years post-HSCT in pre-UMGCCC and post-UMGCCC groups. Results: The incidence of oGVHD was 19.6% pre-UMGCCC and 11.8% post-UMGCCC, corresponding to a nominal 45% lower odds of oGVHD in the post-UMGCCC cohort (odds ratio [OR]= 0.55, 95% confidence interval [CI]: 0.24-1.28, Conclusions: The opening of the UMGCCC Eye Clinic was associated with a nonsignificant reduction in oGVHD odds, corneal, and conjunctival staining in patients 2 years after HSCT. Our results support the importance of integrated eye care in reducing morbidity in patients undergoing HSCT. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.